NRAS Chief Executive, Ailsa Bosworth has said: “The impact on patients’ lives of this negative outcome is significant. It is particularly disappointing given that we and the BSR were not asking for all patients in the moderate – severe group to be given access, but only those with the biomarkers which indicate poorer prognosis and outcomes"
To read more from the statement or download it in full, visit nras.org.uk/news/bsr-nras-j...